Nexwin Biopharma

Nexwin Biopharma is an innovative biotechnology company based in Beijing, China, specializing in the discovery and development of next-generation Targeted Protein Degradation (TPD) therapies. The company focuses on the development of molecular glue degraders, a sophisticated class of small molecules that facilitate the degradation of disease-causing proteins that are currently considered 'undruggable' by traditional inhibitors. Utilizing its proprietary NexGlue platform, the company aims to recruit E3 ligases to specifically target and eliminate pathogenic proteins in oncology and immunology. Founded in 2021 by industry veterans with extensive experience at major pharmaceutical companies like Bristol Myers Squibb and Celgene, Nexwin has secured significant funding from top-tier venture capital firms to advance its pipeline. The company is currently progressing multiple programs through discovery and pre-clinical stages toward clinical trials.